[1]尹丽丹 陈小玲 陈玉成.动脉型肺动脉高压的危险分层评估工具及其临床应用[J].心血管病学进展,2021,(12):1074-1080.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.005]
　YIN Lidan,CHEN Xiaoling,CHEN Yucheng.Risk Stratification Assessment Tools for Pulmonary Arterial Hypertension and Clinical Application[J].Advances in Cardiovascular Diseases,2021,(12):1074-1080.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.005]
点击复制

动脉型肺动脉高压的危险分层评估工具及其临床应用()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年12期
页码:
1074-1080
栏目:
综述
出版日期:
2021-12-25

文章信息/Info

Title:
Risk Stratification Assessment Tools for Pulmonary Arterial Hypertension and Clinical Application
作者:
尹丽丹 陈小玲 陈玉成
(四川大学华西医院心内科,四川 成都 610041 )
Author(s):
YIN Lidan;  CHEN Xiaoling;  CHEN Yucheng
(Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China)
关键词:
动脉型肺动脉高压; 危险分层工具; 临床应用
Keywords:
Pulmonary arterial hypertension; Risk stratification tool; Clinical application
DOI:
10.16806/j.cnki.issn.1004-3934.2021.12.005
摘要:
动脉型肺动脉高压是一类慢性疾病，需长期靶向药物治疗，持续的随访评估对病情变化及靶向药物治疗效果评价尤为重要。目前，国内外指南都推荐将肺动脉高压危险分层工具作为指导药物选择、评价药物治疗反应以及指导治疗方案调整的重要手段。目前肺动脉高压的危险分层工具较多，各有优劣。故本文对常见的肺动脉高压危险分层评估方法以及其临床应用做一综述。
Abstract:
Pulmonary arterial hypertension (PAH) is a chronic disease ,which requires long-term targeted therapy. Continuous follow-up assessment is critically important to evaluate the progression of disease and the response of targeted treatment. Both domestic and foreign guidelines recommend the PAH risk stratification tools as important evidences of guiding drug selection,evaluating drug response and guiding therapy regimen adjustment. At present,there are many risk stratification tools for PAH,each with its own advantages and disadvantages. This article reviews the common methods of PAH risk stratification tools and their clinical applications

参考文献/References:

[1] Galiè N,Humbert M,Vachiery JL,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology (AEPC),International Society for Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J,2016,37(1):67-119.

[2] Ventetuolo CE,Praestgaard A,Palevsky HI,et al. Sex and haemodynamics in pulmonary arterial hypertension[J]. Eur Respir J,2014,43(2):523-530.

[3] Hjalmarsson C,R?degran G,Kylhammar D,et al. Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension[J]. Eur Respir J,2018,51(5):1702310.

[4] Hoeper MM,Huscher D,Ghofrani HA,et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension:results from the COMPERA registry[J]. Int J Cardiol,2013,168(2):871-880.

[5] Evans JD,Girerd B,Montani D,et al. BMPR2 mutations and survival in pulmonary arterial hypertension:an individual participant data meta-analysis[J]. Lancet Respir Med,2016,4(2):129-137.

[6] Chung L,Farber HW,Benza R,et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry[J]. Chest,2014,146(6):1494-1504.

[7] Le Pavec J,Souza R,Herve P,et al. Portopulmonary hypertension:survival and prognostic factors[J]. Am J Respir Crit Care Med,2008,178(6):637-643.

[8] Benza RL,Miller DP,Gomberg-Maitland M,et al. Predicting survival in pulmonary arterial hypertension:insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)[J]. Circulation,2010,122(2):164-172.

[9] Vallerand JR,Weatherald J,Laveneziana P. Pulmonary hypertension and exercise[J]. Clin Chest Med,2019,40(2):459-469.

[10] Wang J,Wang Y,Li X,et al. Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese:a single-center retrospective study[J]. BMC Pulm Med,2020,20(1):272.

[11] Mcglinchey N,Johnson MK. Novel serum biomarkers in pulmonary arterial hypertension[J]. Biomark Med,2014,8(8):1001-1011.

[12] Benza RL,Gomberg-Maitland M,Miller DP,et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension[J]. Chest,2012,141(2):354-362.

[13] D’Alonzo GE,Barst RJ,Ayres SM,et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry[J]. Ann Intern Med,1991,115(5):343-349.

[14] Weatherald J,Boucly A,Chemla D,et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension[J]. Circulation,2018,137(7):693-704.

[15] Raymond RJ,Hinderliter AL,Willis P W,et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension[J]. J Am Coll Cardiol,2002,39(7):1214-1219.

[16] Puntmann V,Valbuena S,Hinojar R,et al. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research:part I—analytical validation and clinical qualification[J]. J Cardiovasc Magn Reson,2018,20(1):67.

[17] Swift A ,Rajaram S,Capener D,et al. LGE patterns in pulmonary hypertension do not impact overall mortality[J]. JACC Cardiovasc Imaging,2014,7(12):1209-1217.

[18] van Wolferen SA,Marcus JT,Boonstra A,et al. Prognostic value of right ventricular mass,volume,and function in idiopathic pulmonary arterial hypertension[J]. Eur Heart J,2007,28(10):1250-1257.

[19] Thenappan T,Shah SJ,Rich S,et al. Survival in pulmonary arterial hypertension:a reappraisal of the NIH risk stratification equation[J]. Eur Respir J,2010,35(5):1079-1087.

[20] Sitbon O,Benza RL,Badesch DB,et al. Validation of two predictive models for survival in pulmonary arterial hypertension[J]. Eur Respir J,2015,46(1):152-164.

[21] Kane GC,Maradit-Kremers H,Slusser JP,et al. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension[J]. Chest,2011,139(6):1285-1293.

[22] R?degran G,Kjellstr?m B,Ekmehag B,et al. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000-2014[J]. Scand Cardiovasc J,2016,50(4):243-250.

[23] Chakinala MM,Coyne DW,Benza RL,et al. Impact of declining renal function on outcomes in pulmonary arterial hypertension:a REVEAL registry analysis[J]. J Heart Lung Transplant,2018,37(6):696-705.

[24] Benza RL,Gomberg-Maitland M,Elliott CG,et al. Predicting survival in patients with pulmonary arterial hypertension:the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies[J]. Chest,2019,156(2):323-337.

[25] Benza RL,Kanwar MK,Raina A,et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator,REVEAL Lite 2,for use in patients with pulmonary arterial hypertension[J]. Chest ,202,159(1):337-346.

[26] Galiè N,Channick RN,Frantz RP,et al. Risk stratification and medical therapy of pulmonary arterial hypertension[J]. Eur Respir J,2019,53(1):1801889.

[27] Kylhammar D,Kjellstr?m B,Hjalmarsson C,et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension[J]. Eur Heart J,2018,39(47):4175-4181.

[28] Peacock AJ,Crawley S,Mclure L,et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy:the EURO-MR study[J]. Circ Cardiovasc Imaging,2014,7(1):107-114.

[29] Boucly A,Weatherald J,Savale L,et al. Risk assessment,prognosis and guideline implementation in pulmonary arterial hypertension[J]. Eur Respir J,2017,50(2):1700889.

[30] Hoeper M M,Kramer T,Pan Z,et al. Mortality in pulmonary arterial hypertension:prediction by the 2015 European pulmonary hypertension guidelines risk stratification model[J]. Eur Respir J,2017,50(2):1700740.

[31] Leuchte HH,Ten Freyhaus H,Gall H,et al. Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension:Updated Recommendations from the Cologne Consensus Conference 2018[J]. Int J Cardiol,2018,272S:20-29.

[32] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南（2021版） [J] . 中华医学杂志,2021,101(1):11-51.

[33] Thomas CA,Anderson RJ,Condon DF,et al. Diagnosis and management of pulmonary hypertension in the modern era:insights from the 6th World Symposium[J]. Pulm Ther,2020,6(1):9-22.

[34] Dardi F,Palazzini M,Gotti E,et al. P4538Simplified table for risk stratification in patients with different types of pulmonary arterial hypertension[J]. Eur Heart J,2018,39(suppl_1):ehy563.

[35] Lewis RA,Johns CS,Cogliano M,et al. Identification of cardiac magnetic resonance imaging thresholds for risk stratification in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2020,201(4):458-468.

[36] Liu BY,Wu WC,Zeng QX,et al. The value of three-dimensional echocardiography in risk stratification in pulmonary arterial hypertension:a cross-sectional study[J]. Int J Cardiovasc Imaging,2020,36(4):577-584.

[37] Wang L,Chen X,Wan K,et al. Diagnostic and prognostic value of right ventricular eccentricity index in pulmonary artery hypertension[J]. Pulm Circ,2020,10(2):2045894019899778.

[38] Farmakis I,Demerouti E,Karyofyllis P,et al. Echocardiography in pulmonary arterial hypertension:is it time to reconsider its prognostic utility?[J]. J Clin Med,2021,10(13):2826.

[39] Alabed S,Shahin Y,Garg P,et al. Cardiac-MRI predicts clinical worsening and mortality in pulmonary arterial hypertension:a systematic review and meta-analysis[J]. JACC Cardiovasc Imaging,2021,14(5):931-942.

[40] Kiely D,Cottreel E,Galiè N,et al. REPAIR:long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH)[C]. ?ERS International Congress 2020 abstracts,2020.

相似文献/References:

[1]朱路 顾玲 刘斌.NLRP3 炎性小体在动脉型肺动脉高压中的研究进展[J].心血管病学进展,2022,(2):158.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.016]
　ZHU Lu,GU Ling,LIU Bin.NLRP3 Inflammasome in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2022,(12):158.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.016]
[2]丁兆慧 奚群英.双能量CT成像技术在肺血管疾病中的应用进展[J].心血管病学进展,2024,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.008]
　DING Zhaohui,XI Qunying.Dual-Energy CT Imaging in Pulmonary Vascular Diseases[J].Advances in Cardiovascular Diseases,2024,(12):27.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.008]

备注/Memo

备注/Memo:
基金项目：四川大学华西医院学科卓越发展135工程项目（ZYJC18013）?div>通信作者：陈玉成，Email:chenyucheng2003@126.com?/div>
收稿时间：2021-06-15
更新日期/Last Update: 2022-01-07